Schenkein David P 4
4 · Denali Therapeutics Inc. · Filed Nov 13, 2024
Insider Transaction Report
Form 4
Schenkein David P
Director
Transactions
- Exercise/Conversion
Common Stock
2024-11-11$18.00/sh+47,165$848,970→ 68,661 total - Sale
Common Stock
2024-11-11$32.09/sh−27,129$870,570→ 41,532 total - Sale
Common Stock
2024-11-11$32.87/sh−32,312$1,062,095→ 9,220 total - Exercise/Conversion
Stock Option (right to buy)
2024-11-11−47,165→ 0 totalExercise: $18.00Exp: 2027-12-06→ Common Stock (47,165 underlying)
Holdings
- 26,232(indirect: See footnote)
Common Stock
- 31,232(indirect: See footnote)
Common Stock
Footnotes (7)
- [F1]Includes 5,967 Unvested RSUs.
- [F2]The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024.
- [F3]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.54 to $32.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.54 to $33.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F5]The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
- [F6]The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
- [F7]25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.